Depression, vertigo, headaches and stroke were among conditions linked to early-onset Alzheimer's disease years before ...
Brent and Erika Pfeiffer are sharing their journey ahead of the Cleveland Walk to End Alzheimer's, hoping to help families ...
Shanghai Fosun Pharmaceuticals secured regional rights to AR1001 via a $60M option fee. Find out why SFOSF stock is a hold.
Learn how Alzheimer's disease is diagnosed through history, testing, imaging, and emerging blood biomarkers to support early ...
Dementia and Alzheimer’s disease are closely related, but the terms describe different things. Dementia is a pattern of problems with memory, thinking or behaviour that interferes with daily life, ...
Asianet Newsable on MSN
Arrowhead’s Alzheimer’s drug shows sharp reduction in disease-linked protein in early trial – here’s what investors need to know
In the Phase 1/2a trial, patients receiving Arrowhead’s drug saw an average 73% reduction in tau protein levels in ...
Clinical Trials Arena on MSN
Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial
Arrowhead is now moving its tau-targeting therapy from healthy volunteers to Alzheimer’s disease patients.
Acta Pharmaceuticals has raised $24 million in total seed financing to advance a pipeline of therapies designed for earlier ...
Award to Dr. Walter Swardfager, from Sunnybrook Research Institute, will support a proof-of-mechanism clinical trial ...
An experimental procedure in China raises hopes — and questions. Plus, new clues about long COVID and how census changes ...
A metabolic byproduct of gut bacteria can damage the blood-brain barrier and drive the formation of Alzheimer's-related ...
Explore the latest Alzheimer’s treatments available at Kingston Health Sciences Centre, designed to slow disease progression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results